The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.

Achieving deep levels of remission is one of the prerequisites to reach long-term survival in solid tumors and hematologic malignancies, and this has also been proved in newly diagnosed multiple myeloma (MM) patients, particularly in the era of novel agents.[1][1]–[3][2] Accordingly, both the